The Christie NHS FT Annual Report & Accounts 2019-20

Research

stone and became so unwell she was confined to bed and in a lot of pain. With no other treatment options available she was put forward for a trial at The Christie with only a 10-15% chance of being eligible. Her tumour DNA was a match for the TAS-120 phase II trial taking led by medical oncologist Professor Juan Valle, a world-leading specialist in biliary tract cancer research. Within three days of taking the oral drug, Kadiatou’s pain had disappeared. Gradually the tumours started to shrink and she was able to lead a normal life again. Kadiatou Diallo said: “Our prayers were answered and I have literally come back to life. The next step for me was the hospice. I now feel well, my hair and eye lashes have grown back and I can enjoy being with my husband, children and my community who have been my backbone when I was so sick.” Professor Juan Valle, added: “It can be very difficult to treat rare cancers like these and the prognosis is usually poor. We do research to improve patients’ lives and find new treatments. We are delighted this drug is extending Kadiatou’s life and keeping the cancer at bay for the time being.”

26